Effects of estrogen, orchidectomy, and cyproterone acetate on tissue fibrinolysis in patients with carcinoma of the prostate.
Twenty-six patients with carcinoma of the prostate were allocated to treatment by subcapsular orchidectomy, estrogen administration, or cyproterone acetate administration. Tissue fibrinolytic activity in skin biopsy specimens was estimated by a histochemical method before treatment was initiated and 2 and 8 weeks later. Orchidectomy caused no significant changes in the fibrinolytic activity. During estrogen therapy the fibrinolytic activity in skin was significantly reduced at 8 weeks. In the group given cyproterone acetate the activity was significantly increased at 8 weeks. In the group given cyproterone acetate the activity was significantly increased at 8 weeks. The reduction in fibrinolytic activity in skin could contribute to the increased risk of thromboembolism during estrogen treatment of patients with cancer of the prostate.
D000368:Aged; D002369:Castration; D003534:Cyproterone / Q000009:adverse effects* / Q000378:metabolism; D004967:Estrogens / Q000009:adverse effects* / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000628:therapy*; D012306:Risk; D012867:Skin / Q000187:drug effects / Q000378:metabolism; D013923:Thromboembolism / Q000209:etiology; D013997:Time Factors
D004967:Estrogens; D003534:Cyproterone